The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, unveiled positive results in its sevasemten programme for Becker and Duchenne muscular dystrophies. The company ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Ron DeSantis on June 25.) It's been a roller coaster of a legislative session in Florida this year.